MannKind 2026 Playbook: Afrezza Label Wins, FUROSCIX Rollout and a Clear Path to Revenue Expansion
MannKind (MNKD) is entering 2026 with tangible commercial catalysts: FDA Afrezza label updates and pediatric acceptance, the ReadyFlow FUROSCIX approval, and the closed scPharmaceuticals acquisition. Those drivers — plus record Q4 revenue and improving technicals — create a structured trade: enter at $5.50, stop at $4.25, target $8.50 over a long-t…